(Incorporated in the Cayman Islands with limited liability)

Stock Code 1177

NOTIFICATION LETTER

26 September 2025

Dear Registered Shareholders,

Sino Biopharmaceutical Limited SP . L
Notice of publication of 2025 Interim Report SP . P . LP. TNLT

now www.sinobiopharm.com and the website of **Stock Exchange** **Website Version** . The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications *(Note)*. If you have elected to receive the Corporate Communications in printed form, the Current Corporate Communication is enclosed.

If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the and transfer office in Hong Kong, Tricor Investor Services Limited (the **Branch Share Registrar** post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to is-ecom@vistra.com. The Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning it to the Branch Share Registrar at the above-mentioned address by post or by email to is-ecom@vistra.com. If the Company does not have your functional email address, until such time that the functional email address is provided to the Branch Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications TNP ; MTNLT and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form.

Should you have any queries relating to this notification, please call the Branch at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays).

Yours faithfully,
For and on behalf of
Sino Biopharmaceutical Limited
Chan Oi Nin Derek
Company Secretary

Note: *Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) Actionable Corporate Communications.*

Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

(www.sinobiopharm.com) (www.hkexnews.hk)

16 17

REPLY FORM

To: **Sino Biopharmaceutical Limited** :
SP . L (Stock Code: 1177) **1177**
(Incorporated in the Cayman Islands with limited liability)
c/o Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road, Hong Kong
16
17

Part A	I/We would like to receive the Current Corporate Communication and all future Corporate Communications in printed form in the manner indicated below:

ONLY ONE of the following boxes)

I/We would like to receive a printed copy **in the English language only; OR**

I/We would like to receive a printed copy **in the Chinese language only; OR**

I/We would like to receive a printed copy **in both the English language and the Chinese language**.

Part B	I/We would like to receive the notices of publication of all future Corporate Communications and Actionable Corporate Communications in electronic form via the email address below:

(Please provide the email address in English BLOCK LETTERS)

Name(s) of Shareholder(s): :	(Please use English BLOCK LETTERS) ( )	Signature: :
Address: :		(Please use English BLOCK LETTERS) ( )
Contact telephone number: :		Date: :

Notes

1. Please complete and sign this Reply F and transfer office in Hong Kong, Tricor Investor Services Limited or via email to is-ecom@vistra.com.
is-ecom@vistra.com
2. Please complete this Reply Form clearly. Any form with no indicated choice, with no signature or otherwise incorrectly completed shall be void. If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this Reply Form in order to be valid.
3. The above instruction for part A will apply to all future Corporate Communications to be sent to you until you notify otherwise by reasonable notice in writing to the Branch Share Registrar or until expired at the end of each financial year of the Company (whichever is earlier). Further request in writing will be required if a shareholder prefers to continue receiving printed copy of future Corporate Communications.
4. If both English and Chinese versions of the Corporate Communications are combined into one document, a printed form of the Corporate Communications with both English and Chinese versions will be sent to the Shareholder requesting for a printed form of any version(s) of the Corporate Communications.
5. If the Company does not possess the email address of a Shareholder or the email address provided is not functional, such Shareholder will be deemed, until such time when such Shareholder has provided a valid and functional email address to the Branch Share Registrar, to have elected to receive a notice of publication of the Corporate Communications by post.
6 For the avoidance of doubt, we do not accept any other special instructions written on this Reply Form.
7. Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the direc rt; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) Actionable Corporate Communications.
(a) (b)
(c) (d) (e) (f) (g)
8. Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

PERSONAL INFORMATION COLLECTION STATEMENT

of processing your instructions as stated in this Reply F The Company may disclose or transfer the Personal Data to its subsidiaries, its Branch Share Registrar and/or third party service provider who provides administrative, computer and other services to the Company for use in connection with the Purposes and to such parties who are authorised by law to request the information or are otherwise relevant for the Purposes and need to receive the information. The Personal Data will be retained for such period as may be necessary to fulfil the Purposes (including for verification and record purposes). Request for access to and/or correction of the Personal Data can be made in accordance with the provisions of the PDPO and any such request should be in writing and sent to the Data Privacy Officer of Tricor Investor Services Limited at the above address.